SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-110949"
 

Search: onr:"swepub:oai:DiVA.org:umu-110949" > Enhancement of the ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Wanders, A. (author)

Enhancement of the effect of low-dose cyclosporin A by sulphasalazine in prevention of cardiac allograft rejection in the rat

  • Article/chapterEnglish1992

Publisher, publication year, extent ...

  • 1992
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-110949
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-110949URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-318448URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Wanders, A Tufveson, G Gerdin, B eng Research Support, Non-U.S. Gov't GERMANY 1992/07/01 Transpl Int. 1992 Jul;5(3):155-8.
  • Sulphasalazine (SASP) is an immunomodulatory compound with disease-modifying activity in ulcerative colitis and in other autoimmune disorders. SASP was previously shown to prolong the survival of heart allografts in rats treated with cyclosporin A (CyA) for 9 days after transplantation. We have now evaluated whether SASP also exerts a beneficial effect under continuous treatment with CyA, when CyA is discontinued after 14 days, or alone if given 10 days prior to transplantation. Cardiac grafts were transplanted from PVG donors to Wistar/Kyoto recipients using an accessory cervical heart transplantation technique. Rejection was defined as the absence of palpable contractions and occurred in the control group in a very reproducible manner on day 8 or 9. SASP alone was given orally (100 mg/kg body weight) starting 10 days before transplantation and resulted in a minor prolongation of graft survival. When SASP was given in addition to oral CyA (1 mg/kg or 2 mg/kg from day 0 to rejection) there was a significant prolongation in graft survival [from medians of 8 (range 6-11) and 9 (range 8-11) days, respectively, to medians of 10 (range 8-15) and 12 (range 11-15) days, respectively]. When SASP was given from day 0 to rejection, in addition to a schedule of oral CyA (10 mg/kg) for 15 days, there was no prolongation of graft survival [median of 30 (range 26-42) days vs median of 32 (26-38) days]. The data show that SASP acts as a weak immunosuppressive agent which enhances the effect of CyA given at a low dose.(ABSTRACT TRUNCATED AT 250 WORDS)

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Tufveson, G. (author)
  • Gerdin, B. (author)

Related titles

  • In:Transpl Int5:3, s. 155-8
  • In:Transplant International5:3, s. 155-80934-08741432-2277

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Wanders, A.
Tufveson, G.
Gerdin, B.
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Other Basic Medi ...
Articles in the publication
Transpl Int
Transplant Inter ...
By the university
Umeå University
Uppsala University

Search outside SwePub

Wikipedia about the author:
A_Wanders
Wanders, A.
en

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view